Pulmonary Hypertension Clinical Trials in Bend, Oregon

5 studies are recruiting for pulmonary hypertension in Bend, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)

    A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease

    Stage
    Phase 3
    Ages
    18 to 85
    Site
    Clinical Research Site, Bend, Oregon
    Locations
    3 in total
    Run by
    Pulmovant, Inc.

    See if you can join NCT07816185 on ClinicalTrials.gov

  2. DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).

    Stage
    Not phased
    Ages
    18 and older
    Site
    Summit Health, Bend, Oregon
    Locations
    71 in total
    Run by
    United Therapeutics

    See if you can join NCT06388421 on ClinicalTrials.gov

  3. Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    USA003, Bend, Oregon
    Locations
    145 in total
    Run by
    Insmed Incorporated

    See if you can join NCT07179380 on ClinicalTrials.gov

  4. An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    USA003, Bend, Oregon
    Locations
    9 in total
    Run by
    Insmed Incorporated

    See if you can join NCT07234032 on ClinicalTrials.gov

  5. An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

    Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.

    Stage
    Not phased
    Ages
    18 to 80
    Site
    Summit Health, Bend, Oregon
    Locations
    23 in total
    Run by
    Liquidia Technologies, Inc.

    See if you can join NCT06129240 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.